Population pharmacokinetics of riociguat in a pediatric population (aged ≥6 years) with pulmonary arterial hypertension.

Body size is the main determinant of PK in growing children, and the model supports clinical data that, for children weighing <50 kg, a bodyweight-adjusted dose of riociguat should be used to achieve a similar exposure to that observed in adults with PAH. This article is protected by copyright. All rights reserved.